Edwards Lifesciences Corp

For the period ended Dec 31, 2025. Filed Feb 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 25, 2026

EW$104.01-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets as of December 31, and

CONSOLIDATED BALANCE SHEETS

(in millions, except par value)

	December 31,
	2025	2024
ASSETS
Current assets
Cash and cash equivalents	$2,938.0	$3,045.2
Short-term investments (Note 8)	1,288.3	930.7
Accounts receivable, net of allowances of $15.0 and $11.6, respectively	659.6	609.1
Other receivables	252.5	118.3
Inventories (Note 6)	1,126.2	1,086.7
Prepaid expenses	135.0	121.0
Other current assets	339.3	347.6
Current assets of discontinued operations (Note 5)	—	26.8
Total current assets	6,738.9	6,285.4
Long-term investments (Note 8)	278.6	307.9
Property, plant, and equipment, net (Note 6)	1,811.9	1,686.0
Operating lease right-of-use assets (Note 7)	102.7	98.2
Goodwill (Note 11)	1,768.6	1,776.7
Other intangible assets, net (Note 11)	1,128.2	1,176.6
Deferred income taxes	1,138.1	992.1
Other assets	730.2	721.6
Non-current assets of discontinued operations (Note 5)	—	10.8
Total assets	$13,697.2	$13,055.3
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable	$227.5	$197.4
Accrued and other liabilities (Note 6)	1,561.7	1,282.4
Operating lease liabilities (Note 7)	24.5	23.4
Current liabilities of discontinued operations (Note 5)	—	2.0
Total current liabilities	1,813.7	1,505.2
Long-term debt (Note 12)	598.3	597.7
Operating lease liabilities (Note 7)	82.6	78.9
Uncertain tax positions (Note 19)	502.7	384.6
Litigation settlement accrual	—	52.7
Other liabilities	362.3	373.3
Total liabilities	3,359.6	2,992.4
Commitments and contingencies (Note 7, Note 12, and Note 20)
Stockholders' equity (Note 16)
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding	—	—
Common stock, $1.00 par value, 1,050.0 shares authorized, 658.7 and 654.8 shares issued, and 580.7 and 588.6 shares outstanding, respectively	658.7	654.8
Additional paid-in capital	2,768.4	2,613.4
Retained earnings	14,240.5	13,167.0
Accumulated other comprehensive loss (Note 17)	(238.3)	(244.5)
Treasury stock, at cost, 78.0 and 66.2 shares, respectively	(7,091.7)	(6,192.3)
Total Edwards Lifesciences Corporation stockholders' equity	10,337.6	9,998.4
Noncontrolling interest (Note 9)	—	64.5
Total stockholders' equity	10,337.6	10,062.9
Total liabilities and equity	$13,697.2	$13,055.3

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.